UK's Evox Gets Lilly Onboard For CNS Exosome Collaboration
Banks $20m Up Front
The US major will work with Evox Therapeutics on potential treatments of neurological disorders using the Oxford-based firm's DeliverEX platform.
You may also be interested in...
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.